Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fuyanshu is a Traditional Chinese Medicine (TCM) patent formulation, typically administered as a capsule. It is primarily indicated for the treatment of chronic pelvic inflammatory disease (PID), specifically the dampness-heat stasis syndrome variant. The formulation is a complex mixture of herbal extracts designed to clear heat, remove dampness, and promote blood circulation to resolve stasis. Clinical evidence suggests that when used in combination with conventional antibiotics, Fuyanshu improves clinical efficacy, reduces recurrence rates, and modulates inflammatory markers such as C-reactive protein (CRP), Interleukin-10 (IL-10), and Interleukin-1β (IL-1β).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fuyanshu.